Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
---|---|---|---|---|---|
Recall/1000 | 26.1 (24.0–28.5) | 20.8 (19.1–22.6) | 22.0 (20.3–23.9) | 21.0 (19.3–22.8) | 22.2 (20.3–24.3) |
False positives/1000 | 20.0 (18.1–22.1) | 14.8 (13.4–16.4) | 15.1 (13.7–16.6) | 15.2 (13.8–16.8) | 16.2 (14.6–18.0) |
Screen-detected cancers/1000 | 6.1 (5.2–7.2) | 5.9 (5.0–6.9) | 6.9 (6.0–8.0) | 5.7 (4.9–6.7) | 5.9 (4.9–7.0) |
Interval cancers/1000 | 1.3 (0.9–1.8) | 1.6 (1.2–2.2) | 1.6 (1.2–2.1) | 2.2 (1.7–2.8) | 2.3 (1.7–3.0) |
Program sensitivity (%)* | 82.0 (75.6–87.0) | 77.1 (70.9–82.4) | 79.8 (74.2–84.4) | 71.1 (64.5–79.8) | 70.8 (63.6–77.1) |
12 month sensitivity (%)** | 90.1 (84.4–93.9) | 92.0 (87.2–95.1) | 93.9a (89.7–96.5) | 87.2 (81.3–91.4) | 84.3a (77.3–89.4) |
Specificity (%) | 98.0a,b,c (97.8–98.2) | 98.5a (98.3–98.7) | 98.5b (98.3–98.6) | 98.5c (98.3–98.6) | 98.4 (98.2–98.5) |
Positive predictive value (%) | 23.5 (20.2–27.3) | 28.7 (25.0–32.7) | 31.5 (27.9–35.3) | 27.3 (23.7–31.1) | 26.7 (22.9–30.8) |